Drug Interactions between Mintezol and Requip XL
This report displays the potential drug interactions for the following 2 drugs:
- Mintezol (thiabendazole)
- Requip XL (ropinirole)
Interactions between your drugs
thiabendazole rOPINIRole
Applies to: Mintezol (thiabendazole) and Requip XL (ropinirole)
MONITOR: Coadministration with drugs that are inhibitors of CYP450 1A2 may increase the plasma concentrations of ropinirole, which is metabolized by the isoenzyme. Ciprofloxacin (500 mg twice a day), a known inhibitor of CYP450 1A2, has been reported to increase the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of ropinirole (2 mg three times a day) by an average of 60% and 84%, respectively, in 12 study subjects. The possibility of prolonged and/or increased pharmacologic effects of ropinirole should be considered.
MANAGEMENT: Pharmacologic response to ropinirole should be monitored more closely whenever a CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the ropinirole dosage adjusted as necessary. Patients should be advised to contact their physician if they experience excessive adverse effects of ropinirole such as agitation, hallucinations, orthostasis, sedation, confusion, or increased dyskinesia, flushing, dry mouth, sweating, and heart rate.
References
- (2001) "Product Information. Noroxin (norfloxacin)." Merck & Co., Inc
- (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
Drug and food interactions
rOPINIRole food
Applies to: Requip XL (ropinirole)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
thiabendazole food
Applies to: Mintezol (thiabendazole)
MONITOR: Coadministration with thiabendazole may increase the plasma concentrations of caffeine. The mechanism is thiabendazole inhibition of the CYP450 1A2 metabolism of caffeine. In ten healthy, nonsmoking volunteers, administration of a single 136.5 mg dose of caffeine in combination with a single 500 mg dose of thiabendazole resulted in a nearly 60% increase in the area under the plasma concentration-time curve (AUC) of caffeine compared to administration without thiabendazole. In addition, the half-life of caffeine was increased from 11.9 to 28.6 hours, and oral clearance was reduced by 67% during coadministration with thiabendazole. The formation of paraxanthine from caffeine, which is primarily mediated by CYP450 1A2, was almost completely abolished until after the thiabendazole was cleared from the system.
MANAGEMENT: Patients should be advised that pharmacologic effects of caffeine may be increased during coadministration with thiabendazole.
References
- Bapiro TE, Sayi J, Hasler JA, et al. (2005) "Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans." Eur J Clin Pharmacol, 61, p. 755-61
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.